Pharmaceutical Practice of Clinical Pharmacists Participated in A Patient with Dermatomyositis and Knee Joint Infection Caused by Talaromycosis Marneffei

OBJECTIVE To provide precise treatment for the patient with dermatomyositis and knee joint infection caused by Talaromycosis marneffei(TM). METHODS Clinical pharmacists participated fully in the treatment of this patient, providing pharmaceutical care in terms of choices about treatment options, drug interactions, therapeutic drug monitoring and adverse reaction monitoring. RESULTS After treatment of voriconazole followed by itraconazole, the blood concentrations of tacrolimus and voriconazole were within the target treatment range during four month follow-up, and the clinical symptoms were significantly improved without serious adverse reactions. CONCLUSION The participation of clinical pharmacists in the formulation of individual medication plan of a patient with dermatomyositis and knee joint infection caused by TM, which promotes rational clinical drug use.